Hiroshi Shiku

Hiroshi Shiku, M.D., Ph,D.

Professor and Chairman, Immuno-gene therapy, Mie University Graduate School of Medicine, Center for Comprehensive Cancer Immunotherapy

Address

2-174, Edobashi, Tsu, Mie, 514-8507
Phone    +59-231-5187, Fax +59-231-5276
E-mail  shiku@clin.medic.mie-u.ac.jp

Key words

  • CHP-nanogel cancer vaccine
  • TCR-gene transduced T cell transfer
  • Exosome

Recent Publications

  1. Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel.　Oncol Lett. 2016 Dec;12(6):4493-4504. doi: 10.3892/ol.2016.5253.
  2. Wang L, Ma N, Okamoto S, Amaishi Y, Sato E, Seo N, Mineno J, Takesako K, Kato T, Shiku H. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 2016 Jul 25;5(9):e1211218.
  3. Kashima H, Momose F, Umehara H, Miyoshi N, Ogo N, Muraoka D, Shiku H, Harada N, Asai A. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643. doi: 10.1371/journal.pone.0156643.
  4. Casey NP, Fujiwara H, Tanimoto K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M. A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy. PLoS One. 2016 Jun 7;11(6):e0156896. doi: 10.1371/journal.pone.0156896.
  5. Momose F, Seo N, Akahori Y, Sawada S, Harada N, Ogura T, Akiyoshi K, Shiku H. Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types. PLoS One. 2016 Apr 21;11(4):e0154134. doi: 10.1371/journal.pone.0154134.
  6. Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, Barrett AJ, Yasukawa M. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia. Clin Cancer Res. 2016 Sep 1;22(17):4405-16. doi: 10.1158/1078-0432.CCR-15-2714.
  7. Sato YT, Umezaki K, Sawada S, Mukai SA, Sasaki Y, Harada N, Shiku H, Akiyoshi K. Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep. 2016 Feb 25;6:21933. doi: 10.1038/srep21933.
  8. Miyauchi K, Tsuchikawa T, Wada M, Abiko T, Kyogoku N, Shichinohe T, Miyahara Y, Kageyama S, Ikeda H, Shiku H, Hirano S. Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy. 2016 May;8(5):527-40. doi: 10.2217/imt-2016-0007.
  9. Akane K, Kojima S, Mak TW, Shiku H, Suzuki H. CD8+CD122+CD49dlow regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity. Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2460-5. doi: 10.1073/pnas.1525098113.
  10. Guidance Development Review Committee.; Working Group for Clinical Studies of Cancer Immunotherapy.; Working Group for Effector Cell Therapy.; Working Group for CMC/Non-clinical Studies.; Working Group for Cancer Vaccines and Adjuvants.; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy.; Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies.. Cancer Sci. 2015 Dec;106(12):1761-71. doi: 10.1111/cas.12819.
  11. Matsuzaki J, Tsuji T, Luescher IF, Shiku H, Mineno J, Okamoto S, Old LJ, Shrikant P, Gnjatic S, Odunsi K. Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015 Oct 8;5:14896. doi: 10.1038/srep14896.
  12. Fujiwara H, Ochi T, Ochi F, Miyazaki Y, Asai H, Narita M, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer. Leukemia. 2015 Dec;29(12):2393-401. doi: 10.1038/leu.2015.155.
  13. Miyazaki K, Yamaguchi M, Imai H, Kobayashi K, Tamaru S, Kobayashi T, Shiku H, Katayama N. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol. 2015 Aug;102(2):188-94. doi: 10.1007/s12185-015-1812-2.
  14. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clin Cancer Res. 2015 May 15;21(10):2268-77. doi: 10.1158/1078-0432.CCR-14-1559.
  15. Nishikawa K, Seo N, Torii M, Ma N, Muraoka D, Tawara I, Masuya M, Tanaka K, Takei Y, Shiku H, Katayama N, Kato T. Interleukin-17 induces an atypical M2-like macrophage subpopulation that regulates intestinal inflammation. PLoS One. 2014 Sep 25;9(9):e108494. doi: 10.1371/journal.pone.0108494.
  16. Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine. 2014 Oct 14;32(45):5901-7. doi: 10.1016/j.vaccine.2014.09.002.
  17. Muraoka D, Harada N, Hayashi T, Tahara Y, Momose F, Sawada S, Mukai SA, Akiyoshi K, Shiku H. Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity.
    ACS Nano. 2014 Sep 23;8(9):9209-18. doi: 10.1021/nn502975r.
  18. Ishihara M, Seo N, Mitsui J, Muraoka D, Tanaka M, Mineno J, Ikeda H, Shiku H. Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor. PLoS One. 2014 Aug 8;9(8):e104669. doi: 10.1371/journal.pone.0104669.
  19. Takano S, Shiomoto S, Inoue KY, Ino K, Shiku H, Matsue T. Electrochemical approach for the development of a simple method for detecting cell apoptosis based on caspase-3 activity. Anal Chem. 2014 May 20;86(10):4723-8. doi: 10.1021/ac403394z.
  20. Kasuya H, Kodera Y, Nakao A, Yamamura K, Gewen T, Zhiwen W, Hotta Y, Yamada S, Fujii T, Fukuda S, Tsurumaru N, Kuwahara T, Kikumori T, Koide Y, Fujimoto Y, Nakashima T, Hirooka Y, Shiku H, Tanaka M, Takesako K, Kondo T, Aleksic B, Kawashima H, Goto H, Nishiyama Y.
  21. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer. Hepatogastroenterology. 2014 May;61(131):599-605.